Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immunomedics (IMMU) - moderated -- Ignore unavailable to you. Want to Upgrade?

To: bobbseytwins2001 who wrote (50180)	2/8/2019 3:32:17 PM
From: dorightbythem	3 Recommendations Recommended By bobbseytwins2001 kdd999 sukit Respond to of 63276

Nothing. My wish is for the Chicken Little, hair on fire discussion to move forward to more substantive issues.

To: bobbseytwins2001 who wrote (50180)	2/8/2019 3:33:51 PM
From: duwhee	1 Recommendation Recommended By diaperdaddy Respond to of 63276

One possibility is that the company has a few G era hold overs that were not able to handle FDA standards. The drug is great, saving lives, but please don't scratch your butt and sniff your finger in front of our inspection team...

To: bobbseytwins2001 who wrote (50180)	2/8/2019 4:05:02 PM
From: kdd999	1 Recommendation Recommended By bobbseytwins2001 Read Replies (1) \| Respond to of 63276

That is why it is so important for patients and doctors to call the fda to git er done. Not sure what is the best way to get the word out, short of posting on every possible tnbc board. Some of the oncologists running tests may have already called in. A few of them have been doing a great job of getting info out in the past. Also, i cannot believe the company is doing nothing on this front. Someone is getting paid to dream up the gigantic billboards, etc. This is totally acceptable practice. Remember what active patient interface boards UCB had, social media up the kazoo for lupus! The current Immu mgmt seems to be aware of all those practices, in contrast to the previous dynasty.